Art

J-GLOBAL ID：202002253512393893   Reference number：20A1159971

Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients

日本人患者の神経線維腫症2型と関連した前庭神経鞘腫のベバシズマブ療法

Author (9)： FUJII Masazumi (Department of Neurosurgery, Fukushima Medical University) ,  ICHIKAWA Masahiro (Department of Neurosurgery, Fukushima Medical University) ,  IWATATE Kensho (Department of Neurosurgery, Fukushima Medical University) ,  BAKHIT Mudathir (Department of Neurosurgery, Fukushima Medical University) ,  YAMADA Masayuki (Department of Neurosurgery, Fukushima Medical University) ,  KUROMI Yosuke (Department of Neurosurgery, Fukushima Medical University) ,  SATO Taku (Department of Neurosurgery, Fukushima Medical University) ,  SAKUMA Jun (Department of Neurosurgery, Fukushima Medical University) ,  SAITO Kiyoshi (Department of Neurosurgery, Fukushima Medical University)
Material： Neurologia Medico-Chirurgica  (神経外科)
Volume： 60  Issue： 2  Page： 75-82(J-STAGE)  Publication year： 2020 
JST Material Number： Z0762A  ISSN： 0470-8105  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： *Bevacizumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A1159971&from=J-GLOBAL&jstjournalNo=Z0762A") }}

Author keywords (3)： bevacizumab ,  neurofibromatosis type 2 ,  vestibular schwannoma

JST classification (2)： Tumors(=neoplasms)of nervous system  (GN04000V) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (18)：

• 1) Evans DG: Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med 11: 599-610, 2009
• 2) Otsuka G, Saito K, Nagatani T, Yoshida J: Age at symptom onset and long-term survival in patients with neurofibromatosis type 2. J Neurosurg 99: 480-483, 2003
• 3) Iwatate K, Yokoo T, Iwatate E, et al.: Population characteristics and progressive disability in neurofibromatosis type 2. World Neurosurg 106: 653-660, 2017
• 4) Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7: 335-345, 2004
• 5) Wong HK, Lahdenranta J, Kamoun WS, et al.: Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70: 3483-3493, 2010

Terms in the title (6)： 日本人 ,  患者 ,  神経線維腫症2型 ,  前庭神経鞘腫 ,  ベバシズマブ ,  療法